Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Cross-reactivity

Cross-reactivity

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Functional Antibody-Dependent Enhancement as an Immune Assessment Platform: Development, Standardization, and Translational Interpretation in Flavivirus Research.

Pathogens (Basel, Switzerland)·2026

Same author

SARS-CoV-2 Evolution: Implications for Diagnosis, Treatment, Vaccine Effectiveness and Development.

Vaccines·2025

Same author

Phagemid-based capsid system for CRISPR-Cas13a antimicrobials targeting methicillin-resistant Staphylococcus aureus.

Communications biology·2024

Same author

Efficient synthesis of CRISPR-Cas13a-antimicrobial capsids against MRSA facilitated by silent mutation incorporation.

Scientific reports·2024

Same author

Metabolic remodeling by RNA polymerase gene mutations is associated with reduced β-lactam susceptibility in oxacillin-susceptible MRSA.

mBio·2024

Same author

Utility of an In-Vitro Micro-Neutralizing Test in Comparison to a Plaque Reduction Neutralization Test for Dengue Virus, Japanese Encephalitis Virus, and Zika Virus Serology and Drug Screening.

Pathogens (Basel, Switzerland)·2024

Same journal

Correction: Fukushima et al. Long-Term Immunogenicity of Rabies Pre-Exposure Prophylaxis in Japanese Adult Travelers: Comparison of Dosing Regimens. <i>Vaccines</i> 2025, <i>13</i>, 1169.

Vaccines·2026

Same journal

Access to Vaccines Among Asylum Seekers, Refugees, and Undocumented Migrants Across the Migratory Cycle in the European Union, European Economic Area, Switzerland and the United Kingdom: A Scoping Review.

Vaccines·2026

Same journal

Advances in Detection Methods for Human Respiratory Syncytial Virus Neutralizing Antibodies.

Vaccines·2026

Same journal

Insights from 25 Years of Measles and Measles-Rubella Vaccination Campaigns in the WHO African Region (2001-2025).

Vaccines·2026

Same journal

Post-Marketing Safety Surveillance of Influenza Vaccines in Anhui Province, China, 2016-2025.

Vaccines·2026

Same journal

Characteristics of Hypotonic-Hyporesponsive Episodes (HHEs) Following Childhood Vaccination: A 13-Year Analysis of Spontaneous Reports to the Dutch Pharmacovigilance Centre Lareb.

Vaccines·2026

See all related articles

Search research articles

Related Experiment Video

Updated: Jan 10, 2026

Production of E. coli-expressed Self-Assembling Protein Nanoparticles for Vaccines Requiring Trimeric Epitope Presentation

Production of E. coli-expressed Self-Assembling Protein Nanoparticles for Vaccines Requiring Trimeric Epitope Presentation

Published on: August 21, 2019

T-Cell-Based Universal Dengue Vaccine Design for Robust Protective Response.

Yi Fei Sun¹, Adeline Yeo Syin Lian¹, Meng Ling Moi¹

¹Department of Developmental Medical Sciences, Graduate School of Medicine, The University of Tokyo, Tokyo 113-0033, Japan.

|November 26, 2025

Summary

This summary is machine-generated.

Developing novel T-cell epitope vaccines targets conserved regions of dengue virus non-structural proteins. This approach aims for safer, cross-protective dengue vaccines by mimicking natural immunity and avoiding antibody-dependent enhancement.

Keywords:

T-cell epitope-based vaccine antibody-dependent enhancement dengue fever epitope prediction next-generation platforms serotype diversity

More Related Videos

Evaluation of Zika Virus-specific T-cell Responses in Immunoprivileged Organs of Infected Ifnar1-/- Mice

Evaluation of Zika Virus-specific T-cell Responses in Immunoprivileged Organs of Infected Ifnar1-/- Mice

Published on: October 17, 2018

Targeted Antibody Blocking by a Dual-Functional Conjugate of Antigenic Peptide and Fc-III Mimetics DCAF

Targeted Antibody Blocking by a Dual-Functional Conjugate of Antigenic Peptide and Fc-III Mimetics DCAF

Published on: September 17, 2019

Related Experiment Videos

Last Updated: Jan 10, 2026

Production of E. coli-expressed Self-Assembling Protein Nanoparticles for Vaccines Requiring Trimeric Epitope Presentation

Production of E. coli-expressed Self-Assembling Protein Nanoparticles for Vaccines Requiring Trimeric Epitope Presentation

Published on: August 21, 2019

Evaluation of Zika Virus-specific T-cell Responses in Immunoprivileged Organs of Infected Ifnar1-/- Mice

Evaluation of Zika Virus-specific T-cell Responses in Immunoprivileged Organs of Infected Ifnar1-/- Mice

Published on: October 17, 2018

Targeted Antibody Blocking by a Dual-Functional Conjugate of Antigenic Peptide and Fc-III Mimetics DCAF

Targeted Antibody Blocking by a Dual-Functional Conjugate of Antigenic Peptide and Fc-III Mimetics DCAF

Published on: September 17, 2019

Area of Science:

Immunology
Vaccinology
Virology

Background:

Dengue virus poses a significant global health challenge, with current vaccines exhibiting limitations in efficacy and safety.
Traditional antibody-based vaccines may offer insufficient protection and risk enhancing disease severity in naive individuals.

Purpose of the Study:

To explore a new generation of T-cell epitope-based vaccines for dengue virus.
To develop a safer and more broadly protective dengue vaccine candidate.

Main Methods:

Focusing on conserved peptide regions within dengue virus non-structural proteins (NS3 and NS5) across all serotypes.
Utilizing immunoinformatics to identify potent T-cell epitopes with high HLA binding affinity and cross-serotype conservation.
Integrating selected epitopes into advanced delivery systems like mRNA and nanoparticles.

Main Results:

Identified specific peptides (e.g., DTTPFGQQR, KPGTSGSPI, MYFHRRDLRL) that elicit strong cytotoxic and helper T-cell responses.
Demonstrated potential for inducing viral clearance and long-term immune memory.
Proposed delivery systems enhance antigen presentation and stability while mitigating risks of antibody-dependent enhancement.

Conclusions:

T-cell epitope-based vaccines targeting conserved viral regions offer a promising strategy for dengue prevention.
This approach aims to achieve balanced cellular and humoral immunity, similar to natural infection.
The developed vaccine design represents a rational pathway toward a safer, cross-protective, and durable dengue vaccine.